Publicacións nas que colabora con Francisco Javier García Seara (75)

2025

  1. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

    European Journal of Clinical Investigation, Vol. 55, Núm. 4

  2. Prevalence and relevance of H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study

    Heart, Vol. 111, Núm. 4, pp. 159-165

  3. Simplified 3-ganglionated plexus ablation for the treatment of recurrent vasovagal syncope and functional bradyarrhythmia

    Heart Rhythm

  4. Single-chamber pacemakers: with or without leads? Cost-effectiveness and cost-utility analyses

    Annals of Medicine, Vol. 57, Núm. 1

  5. Soluble guanylate cyclase stimulation improves cardiac function and mitochondrial activity in a rat model of early-stage heart failure with preserved ejection fraction

    Biomedicine and Pharmacotherapy, Vol. 191

2024

  1. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction

    Biochemical Pharmacology, Vol. 230

  2. Effect of age on clinical impact and mid-term denervation in patients undergoing cardioneuroablation

    Scientific Reports, Vol. 14, Núm. 1

  3. Pseudotransposition of the great leads

    PACE - Pacing and Clinical Electrophysiology, Vol. 47, Núm. 2, pp. 233-235

2023

  1. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 3055-3066

  2. Circulating miR-451a Expression May Predict Recurrence in Atrial Fibrillation Patients after Catheter Pulmonary Vein Ablation

    Cells, Vol. 12, Núm. 4

  3. Clinical and cost-effectiveness results of an on-call program for pacemaker implantations

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 936-937

  4. Plasma miR-486-5p Expression Is Upregulated in Atrial Fibrillation Patients with Broader Low-Voltage Areas

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  5. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  6. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

    European Journal of Internal Medicine, Vol. 99, pp. 45-56

  2. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

    BMC Medicine, Vol. 20, Núm. 1

  3. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 5, pp. 721-728

  4. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 7

  5. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 6

  6. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1